In this C+D podcast, hosted by Managing Editor Nana Ofori-Atta, talks to Matthew Rawding, the medical cannabis specialist pharmacist about Curaleaf's pharmacy cannabis scheme.

The episode explores the implications of this move, including regulatory challenges, the potential impact on patients, and the broader industry shift toward integrating cannabis into mainstream healthcare.

The podcast provides a critical analysis of Curaleaf's strategy, raising important questions about the future of cannabis in the pharmaceutical space.